News

PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE® IBDCambridge, UK, 02 February: PredictImmune,...

PredictImmune announces commercial partnership with Cambridge Clinical Laboratories (CCL) to promote and supply PredictSURE® IBD, the world’s first...

PredictImmune PROFILE trial recruits over 200 patientsThe first biomarker stratified study for Crohn’s disease, funded by Wellcome Trust, reaches...

PredictImmune pleased to announce the appointment of James Clark as Chief Technology OfficerCambridge, UK, 14 November 2019: PredictImmune,...

PredictImmune and the Crohn’s & Colitis Foundation announce start of jointly- sponsored study to validate PredictSURE® IBD, the first prognostic...

PredictImmune appoints Steven S. Martin as non-executive directorManaging Partner of Paxton Advisors, LLC and ex-CEO of Blue Cross and Blue Shield...

PredictImmune announces a strategic agreement with Theradiag for French speaking Europe to commercialise PredictSURE® IBD, the world’s first...

PredictImmune announces new strategic partnership to commercialise its PredictSURE® IBD prognostic test for inflammatory bowel disease across North...

PredictImmune announces new ‘framework agreement’ with Cambridge Enterprise to allow future expansion of original IP license to expand its...